Achillion Hepatitis C Drug Trial on Hold on Liver Concern

Achillion Pharmaceuticals Inc. fell the most in six years after a trial of one of its experimental hepatitis C drugs was delayed because of abnormal liver results.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.